Drug Trial Radar · NCT03191682
A First-in-Human Study of PRL3-ZUMAB
Last checked: Nov 20, 2026Latest source record: Sep 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
38
Planned (sponsor's estimate)
Start
Feb 20, 2017
Primary completion
Feb 20, 2027
Study completion Feb 20, 2027
Sponsor
- Lead sponsor
- National University Hospital, SingaporeAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- INTRA-IMMUSG PRIVATE LIMITED
- First posted
- Jun 19, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 21 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is carried out to test the safety of a study drug called PRL3-ZUMAB. PRL3-ZUMAB is an investigational drug that has not yet been approved by the Food and Drug Administration (FDA) or any other regulatory authorities for commercial purposes. This is the first study in which PRL3-ZUMAB will be given to humans. The study drug has been tested in animals and was found to be well-tolerated with minimal side effects. This research study will test different doses of the drug to see which dose is safest in people.
Conditions
- Advanced Solid Tumors
Interventions
PRL3-ZUMABDrug
The starting dose will be 0.3 mg/kg, administered Q2 weekly, with the subsequent dose levels being 0.9 mg/kg, 3.0 mg/kg, and 6.0 mg/kg, all administered on a Q2 weekly basis until disease progression. The investigator will monitor each subject for the occurrence of AEs. In event of infusion-related adverse events, the Investigator, in consultation with the PI, may increase the duration of the infusion over a period of up to 24 hours at their discretion. Dosing will continue in a standard 3+3 design for dose escalation.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Grade 3 or 4 drug related adverse events and clinical lab abnormalities defined as Dose Limiting Toxicities (DLTs) using NCI CTCAE v 4.03Time frame: During cycle 1 (28 days) of treatment
- Maximum tolerated dose of PRL3-zumab, defined as the highest dose level at which < 33% of 6 patients experience a dose-limiting toxicity graded according to Common Terminology Criteria for Adverse Events version 4 (Phase I)Time frame: 28 days
- Recommended Phase 2 Dose (RP2D) of PRL3-zumab defined as the most appropriate dose to maximize a favorable risk/benefit reward for the participant populationTime frame: After completion of all Cycle 1 (28 days) of treatment for participant enrolled in part 1
Locations
1 site in 1 country. Site status is shown where the registry gives one.
National University Hospital
Singapore, Singapore, Singapore
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.